Restylane Contour

Galderma Group AG has reported positive topline results from a 162-patient Chinese study of Restylane Volyme for moderate-to-severe temple hollowing, with 94.4% of treated patients meeting the primary responder definition at six months. The data could support another indication for a product already sold in China for mid-face volumization, strengthening Galderma’s attempt to expand its injectable aesthetics business in one of its strategically important international markets.